FDA Approves ZYPREXA RELPREVV — H2-Pharma LLC

# FDA Approves H2-Pharma's ZYPREXA RELPREVV Long-Acting Injectable Formulation H2-Pharma LLC received FDA approval for ZYPREXA RELPREVV (olanzapine pamoate), an intramuscular long-acting antipsychotic injection that extends treatment intervals and addresses patient compliance challenges in the schizophrenia and bipolar disorder markets. The approval positions H2-Pharma to compete in the growing long-acting injectable segment, potentially capturing market share from oral formulations while improving outcomes in patient populations with